Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7054637 | 0.89 | TSHR (0.46) | TSHRIDO1AGXTMAOBALDH1A1 | |
| SCHEMBL1535619 | 0.89 | TSHR (0.46) | TSHRIDO1AGXTMAOBALDH1A1 | |
| SCHEMBL114175 | 0.85 | TSHR (0.48) | TSHRIDO1AGXTMAOBALDH1A1 | |
| SCHEMBL1933327 | 0.84 | TSHR (0.52) | TSHRIDO1AGXTMAOBALDH1A1 | |
| SCHEMBL6873209 | 0.81 | TSHR (0.55) | TSHRIDO1AGXTMAOBALDH1A1 | |
| SCHEMBL7054396 | 0.80 | TSHR (0.43) | TSHRIDO1AGXTALDH1A1SLC6A2 | |
| SCHEMBL25293204 | 0.79 | TSHR (0.52) | TSHRIDO1AGXTMAOBALDH1A1 | |
| SCHEMBL901056 | 0.79 | TSHR (0.52) | TSHRIDO1AGXTMAOBALDH1A1 | |
| SCHEMBL5954673 | 0.79 | TSHR (0.52) | TSHRIDO1AGXTMAOBALDH1A1 | |
| SCHEMBL2068701 | 0.79 | TSHR (0.52) | TSHRIDO1AGXTMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2359862-B1 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES INC (US) | 2013-07-24 | — | — | EP | claimed |
| EP-2502941-A1 | Heterobifunctional poly (ethylene glycol) and uses thereof | Intezyne Technologies Inc. (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2359862-A1 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | Intezyne Technologies Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| EP-2348096-A2 | Synthesis of hybrid block copolymers and uses thereof | Intezyne Technologies Inc. (US) | 2011-07-27 | — | — | EP | claimed |
| EP-2073850-B1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES INC (US) | 2010-10-27 | — | — | EP | claimed |
| JP-2010526183-A | — | — | 2010-07-29 | — | — | JP | claimed |
| EP-2152320-A2 | ENCAPSULATED CONTRAST AGENTS | Intezyne Technologies Incorporated (US) | 2010-02-17 | — | — | EP | claimed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | claimed |
| EP-1907444-B1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES INC (US) | 2009-08-19 | — | — | EP | claimed |
| EP-2073850-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | Intezyne Technologies Incorporated (US) | 2009-07-01 | — | — | EP | claimed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | claimed |
| WO-2008134734-A2 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | claimed |
| WO-2008134731-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2008106657-A2 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| EP-1907444-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | Intezyne Technologies Incorporated (US) | 2008-04-09 | — | — | EP | claimed |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. | 2006-10-26 | — | — | US | claimed |
| WO-2006107903-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-10-12 | — | — | WO | claimed |
| US-20060172914-A1 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-08-03 | — | — | US | claimed |
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | GNE, ALG1, EPHX2 | TSHR 4037/4885IDO1 2037/4885AGXT 941/4885 |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | TSHR 3790/4885IDO1 4405/4885AGXT 1292/4885 |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | ABCB1, TERT, ABCB4 | TSHR 2517/4885IDO1 4696/4885AGXT 1427/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | TSHR 4361/4885IDO1 3888/4885AGXT 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.